JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy ...
$220.9 million cash and cash equivalents as of June 30, 2025 supports cash runway through 2027, including multiple clinical inflection points SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 13, ...
Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its ...
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results